Omalizumab
Information about Omalizumab[edit source]
Omalizumab is a monoclonal antibody to human immunoglobulin E (IgE), which leads to a decrease in IgE binding to mast cells and basophils and a reduction in allergic symptoms of asthma and seasonal rhinitis.
Liver safety of Omalizumab[edit source]
Omalizumab therapy has not been associated with serum enzyme elevations during therapy and has yet to be implicated in cases of clinically apparent drug induced liver injury with jaundice.
Mechanism of action of Omalizumab[edit source]
Omalizumab (oh” ma liz’ ue mab) is a recombinant, human monoclonal antibody to IgE which binds avidly to circulating immunoglobulin E, preventing its attachment to high affinity receptors on mast cells and basophils. This receptor inhibition prevents the release of histamine and other mediators of the allergic immune response, reducing airway inflammation and spasm and alleviating symptoms of asthma and allergic rhinitis. Therapy with omalizumab has been shown to reduce the requirement for inhaled corticosteroids and lower the frequency of exacerbations of asthma and to decrease the severity and symptoms of chronic urticaria of unknown cause.
FDA approval information for Omalizumab[edit source]
Omalizumab was approved for use in the United States in 2003 for therapy of patients with severe and persistent asthma despite corticosteroid inhalation therapy. The indications were extended in 2014 to include chronic idiopathic urticaria. Omalizumab has been evaluated in patients with seasonal rhinitis, but has yet to be approved for that use. Omalizumab is available in single use vials of 150 mg under the brand name Xolair.
Dosage and administration for Omalizumab[edit source]
The recommended dose is 150 to 300 mg intravenously every 4 weeks or 225 to 375 mg every 2 weeks based upon body weight and IgE levels.
Side effects of Omalizumab[edit source]
Common side effects include injection site reactions, rash, diarrhea, nausea and vomiting and epistaxis. Rarely, omalizumab can cause serious acute anaphylaxis or anaphylactoid reactions (~ 0.1%) and should be given under close medical supervision. Beta-2 Adrenergic Agonists
Albuterol, Bitolterol, Formoterol, Metaproterenol, Pirbuterol, Salbutamol, Salmeterol, Terbutaline
Leukotriene Receptor Antagonists
Benralizumab, Mepolizumab, Omalizumab, Reslizumab
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Kondreddy Naveen, Prab R. Tumpati, MD
